Industry News Johnson & Johnson / Ollin Biosciences Endpoints News

J&J Pays Up to $3.3B for Ollin to Fill Its Retina Gap

  • Johnson & Johnson will acquire Ollin Biosciences for roughly $2.2B upfront plus up to about $1.1B in regulatory and commercial milestones; closing is expected by year-end.
  • Ollin's lead, OLN324, is a bispecific antibody for diabetic macular edema and wet AMD; the company says an early head-to-head study beat Roche's Vabysmo on anatomy and vision.
  • A separate Blackstone Life Sciences agreement provides $750M of multi-year funding for late-stage development, in exchange for payments and royalties.
Points Based on public reports

J&J has contact lenses and surgical vision but no retinal drug, so it is buying its way into the Vabysmo/Eylea market rather than building there. Note that the Blackstone money sits outside the headline price: the real net cost and the royalty drag depend on terms we can't see. The pitch rests on Ollin's own cross-study claim against Vabysmo, and the dosing interval, not just efficacy, will decide whether retinal specialists switch.